Research Use Only. Peptides Lab UK supplies research-grade materials for in-vitro laboratory research only. Nothing on this page is medical advice or an instruction for human or animal use, and no product sold on this website is a medicine.
Abstract
This review summarises peer-reviewed literature on Semaglutide, with a focus on pharmacology and the published clinical literature. It describes receptor pharmacology, preclinical findings and outcomes reported in published randomised controlled trials, and notes limitations of the current evidence. It does not provide dosing, administration or preparation information.
Background
Semaglutide is a long-acting GLP-1 receptor agonist analogue, engineered with fatty-acid side-chain acylation and amino-acid substitution to enable albumin binding and resistance to DPP-4 degradation. It is an authorised prescription-only medicine in the UK for specific indications under medical supervision; research-grade material is not a medicinal product.[1]
Mechanism of action
Semaglutide activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, in the gastrointestinal tract and in brain regions involved in appetite regulation. GLP-1 receptor signalling enhances glucose-dependent insulin secretion, suppresses glucagon secretion and slows gastric emptying.[1,2]
Summary of published research
Semaglutide – Published clinical trial outcomes: body weight
In STEP 1 (68 weeks, adults with overweight or obesity without diabetes), the mean change in body weight was −14.9% with semaglutide 2.4 mg weekly versus −2.4% with placebo, alongside lifestyle intervention in both groups.[3]
Semaglutide – Published research: MASH
In the phase 3 ESSENCE trial (biopsy-defined MASH with F2–F3 fibrosis), resolution of steatohepatitis without worsening of fibrosis at week 72 occurred in 62.9% with semaglutide versus 34.3% with placebo, and fibrosis improvement in 36.8% versus 22.4%.[4]
Semaglutide – Published research: cardiovascular outcomes
SUSTAIN-6 reported a lower rate of major adverse cardiovascular events (MACE) with semaglutide versus placebo in type 2 diabetes at high cardiovascular risk (HR 0.74). SELECT, in people with established cardiovascular disease and overweight or obesity without diabetes, reported a 20% relative reduction in MACE (HR 0.80).[5,6]
Semaglutide – Published research: kidney outcomes
The FLOW trial in type 2 diabetes and chronic kidney disease was stopped early for efficacy; semaglutide reduced the risk of the primary composite kidney outcome by 24% versus placebo (HR 0.76).[7]
Semaglutide – Reported adverse events in trials
In STEP and SUSTAIN trials, gastrointestinal events (nausea, diarrhoea, vomiting, constipation) were the most common adverse events, generally transient and mild to moderate. Gallbladder-related events were reported more often than with placebo in some trials.[3,5]
Limitations of the evidence
Most clinical data come from industry-sponsored trials of defined pharmaceutical formulations under medical supervision; results cannot be extrapolated to research-grade material, which is not manufactured to medicinal GMP standards. Trial populations, durations and comparators differ, so cross-trial comparisons should be interpreted cautiously. Longer-term safety data for newer agents remain limited.
Conclusion
The published literature characterises these peptides as potent incretin-pathway receptor agonists with substantial bodies of preclinical and clinical-trial data. For laboratory work, researchers should rely on primary publications and verified analytical documentation (HPLC/MS certificates of analysis) for any material used.
References
- Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015; 58(18):7370-80. doi:10.1021/acs.jmedchem.5b00726 PMID: 26308095.
- Drucker DJ et al. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27(4):740-756. doi:10.1016/j.cmet.2018.03.001 PMID: 29617641.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384(11):989-1002. doi:10.1056/NEJMoa2032183 PMID: 33567185.
- Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025; 392(21):2089-2099. doi:10.1056/NEJMoa2413258 PMID: 40305708.
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. doi:10.1056/NEJMoa1607141 PMID: 27633186.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023; 389(24):2221-2232. doi:10.1056/NEJMoa2307563 PMID: 37952131.
- Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024; 391(2):109-121. doi:10.1056/NEJMoa2403347 PMID: 38785209.
Disclaimer: All products sold by Peptides Lab UK are for laboratory research use only. Not for human or veterinary use, not for consumption, and not intended to diagnose, treat, cure or prevent any disease. This page is an educational literature summary and is not medical advice.
